Scholarlink

Background <p>We aimed to investigate the prognostic value of the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) Score in early-stage colon cancer.</p> Material-methods <p>A total of 335 patients diagnosed with stage II-III colon cancer between January 2010 and May 2023 were included in this retrospective study. Demographic and clinicopathological characteristics of the patients were recorded, and the HALP score was calculated for each patient. The optimal cut-off value for the HALP score was 25.1 (AUC: 0.62) in ROC analysis. The patients with HALP scores (≤ 25.1) were defined as the “low-HALP group” and those (&gt; 25.1) as the “high-HALP group”. They were compared for clinicopathological characteristics and survival outcomes.</p> Results <p>Median follow-up was 67 months. 5-year disease-free survival (DFS) and overall survival (OS) rates were 68.7% and 79.1%. Higher stage at diagnosis was inversely correlated with survival. Stage III patients had lower DFS and OS than stage II patients: 5-year DFS was 63.8% versus 75.0% (<i>p</i> = 0.043) and 5-year OS was 75.9% versus 83.1% (<i>p</i> = 0.047), respectively. Age (<i>p</i> = 0.002), obstruction at presentation (<i>p</i> &lt; 0.001), and HALP score [HR: 1.83 (95% CI: 1.15–2.90); <i>p</i> = 0.010] were independent prognostic factors for OS in multivariate analysis.</p> Conclusion <p>This study confirms that a low (<i>≤</i> 25.1) HALP score is an independent poor prognostic factor in early-stage colon cancer. As an easily accessible and feasible test derived from routine blood parameters, the HALP score may aid risk stratification. However, given its modest discriminative ability and the lack of external validation, prospective multicenter studies are needed before it can be integrated into clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical significance of the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score as a prognostic indicator in early-stage colon cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Alper Turkel,
  • Ergin Aydemir,
  • Mutlu Dogan

摘要

Background

We aimed to investigate the prognostic value of the Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) Score in early-stage colon cancer.

Material-methods

A total of 335 patients diagnosed with stage II-III colon cancer between January 2010 and May 2023 were included in this retrospective study. Demographic and clinicopathological characteristics of the patients were recorded, and the HALP score was calculated for each patient. The optimal cut-off value for the HALP score was 25.1 (AUC: 0.62) in ROC analysis. The patients with HALP scores (≤ 25.1) were defined as the “low-HALP group” and those (> 25.1) as the “high-HALP group”. They were compared for clinicopathological characteristics and survival outcomes.

Results

Median follow-up was 67 months. 5-year disease-free survival (DFS) and overall survival (OS) rates were 68.7% and 79.1%. Higher stage at diagnosis was inversely correlated with survival. Stage III patients had lower DFS and OS than stage II patients: 5-year DFS was 63.8% versus 75.0% (p = 0.043) and 5-year OS was 75.9% versus 83.1% (p = 0.047), respectively. Age (p = 0.002), obstruction at presentation (p < 0.001), and HALP score [HR: 1.83 (95% CI: 1.15–2.90); p = 0.010] were independent prognostic factors for OS in multivariate analysis.

Conclusion

This study confirms that a low (≤ 25.1) HALP score is an independent poor prognostic factor in early-stage colon cancer. As an easily accessible and feasible test derived from routine blood parameters, the HALP score may aid risk stratification. However, given its modest discriminative ability and the lack of external validation, prospective multicenter studies are needed before it can be integrated into clinical practice.